Parkinson's Disease Clinical Trial
— EILTOfficial title:
Effectiveness of High-frequency Specific Speech Therapy on Verbal Fluency Decline and/ or Verbal Apraxia in Patients With Parkinson's Disease With and Without Deep Brain Stimulation (DBS) - a Randomized Controlled Single-blinded Trial
NCT number | NCT02935842 |
Other study ID # | EILT |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 1, 2016 |
Est. completion date | October 24, 2018 |
Verified date | May 2020 |
Source | University Hospital, Basel, Switzerland |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Due to Parkinson's Disease (PD) speech and language (SL) deficits may occur. Further, the
literature reports that PD patients, who have not undergone deep brain stimulation (DBS),
have deficits regarding voice quality (e.g. loudness and intelligibility of their voice),
while PD patients who have undergone DBS suffer from deficits in word retrieval and speech
apraxia symptoms. To-date, therapeutic approaches focusing specifically on SL deficits
observed in PD-DBS patients are yet to be developed and evaluated.
Therefore, this study investigates the short-and longterm effectiveness of specific and
intensive, high-frequency speech-language therapy in terms of reducing SL-deficits compared
to a nonspecific and non-verbal sham treatment (i.e. a rhythmic balance-movement training
(rBMT)) as well as to a 'no-therapy' condition.
Status | Completed |
Enrollment | 38 |
Est. completion date | October 24, 2018 |
Est. primary completion date | September 12, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 45 Years to 80 Years |
Eligibility |
Inclusion Criteria for all groups: - The patient is able to cooperate - The patient has the mental competence to provide informed consent to participate in the study - The patient speaks and understands German Specific Inclusion Criteria for the DBS Group - Fulfilling the above stated inclusion criteria as stated in a, b and c above - The patient is responsive to Levodopa (L-DOPA) - Having received or being scheduled for DBS Exclusion Criteria: - Severe psychiatric disease difficult to treat (compulsive disorder, depression, mania, psychosis, anxiety as outlined in International Classification of Diseases (ICD-10) (WHO 2015, current version). - Patient with dementia (DMS-V, Mini-Mental-Status-Test (MMS) <24, Montreal Cognitive Assessment (MoCa) <21) - Secondary Parkinsonism - Age =18 years - Pregnancy (early onset) - Presence of a known disease other than PD that shortens the life expectancy - Mental incompetence to provide informed consent to participate in the study - Previous intracranial surgery - Epilepsy - Contraindications for DBS seen in MRI-scan (malignant tumour, severe microvascular disease) - Insufficient skills of German language for participating in neuropsychological evaluations - Sensory problems, severe enough to significantly interfere with neuropsychological assessment - Alcohol and/or drug addiction |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital Basel | Basel | BS |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Basel, Switzerland |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Velocity in Gait | Gait Velocity: meters per second | At Baseline (BL), T1 after 4 weeks (4W-directly after intervention), T2 after 6 months (6M). | |
Primary | Cadence in Gait | 4-Weeks and 6-Months Follow-up. To measure rhythmicity in gait, participants walked 6 metres at their individual pace. They were timed and amount of steps were counted. | At Baseline (BL), T1 after 4 weeks (4W-directly after intervention), T2 after 6 months (6M). | |
Primary | Speech Velocity | Speech Velocity at 4 weeks and at 6 months To measure rhythmicity in speech, participants read a text aloud ('the north wind and the sun') and were recorded using an Olympus. According to these speech samples, the count of elicited syllables per second was calculated. |
At Baseline (BL), T1 after 4 weeks (4W-directly after intervention), T2 after 6 months (6M). | |
Primary | Speech Cadence | Speech Cadence 4 Weeks and at 6 Months To measure rhythmicity in speech, participants' speech was recorded while reading a text aloud ('the north wind and the sun'). Elicited syllables per inspiration were analysed. | At Baseline (BL), T1 after 4 weeks (4W-directly after intervention), T2 after 6 months (6M). | |
Secondary | Health Status (UPDRS) | The complete questionnaire 'Unified Parkinson's Disease Rating Scale' (UPDRS) was filled out at BL and 6M. Scores may range from 0-4 per question. Final scores may add up to 199 points maximum. The higher the score, the worse disease severity/ degree of disability is. |
At Baseline and 6 Months | |
Secondary | Neuropsychiatric Self-rating Questionnaires | Self-rating questionnaires investigating depression using the Beck's Depression Inventory (BDI). This is a 21 question, multiple choice, self-report questionnaire. Minimum score is 0 and maximum scores is 63. The higher the score the more severe is the depression. Details: 0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. |
At 4 Weeks and 6 Months | |
Secondary | Neuropsychological Standardised Test Battery | Inhibition Control (Stroop), Visio-Construction (Mosaic), Flexibility (Trail Making Test), Episodic Memory (Basel Verbal Learning Test -long delayed free recall), Working Memory (backwards digit span task by Wechsler). Scores were standardized (z-scores) to a mean of 0 and standard deviation of 1. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean of a reference population. Negative numbers indicate values lower than the reference population and positive numbers indicate values higher than the reference population |
At 4 Weeks and at 6 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Terminated |
NCT02924194 -
Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A |